Latest Breaking News On - National prevalence of fungal diseases - Page 1 : comparemela.com

About Arix Bioscience plc Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.   We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com   Pfizer Acquires Amplyx Pharmaceuticals Opportunity to advance Pfizer s expertise and deep heritage in infectious disease NEW YORK Pfizer Inc. (NYSE: PFE) announced today that it has acquired Amplyx Pharmaceuticals, Inc., a privately-held company dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyx s lead compound, Fosmanogepix (APX001), is a novel investigational asset

City ofUnited kingdomSupriya mathurAboutarix bioscienceCharlotte parryShabnam bashirEamonn nolanArix bioscienceAngela lukinMary clarkChuck trianoAmplyx pharmaceuticals incNational prevalence of fungal diseasesAmplyx pharmaceuticalsGlobal health data exchangeInstitute for health metrics